A prospective randomised pilot study evaluating the safety of the novel LubriShield™ Foley catheter: a permanently coated indwelling urinary catheter
Scandinavian Journal of Urology · 2025
DOI: 10.2340/sju.v60.43994 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Scandinavian Journal of Urology, 2025. Verfasst von Anders Andreasson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Regi…. Hauptthemen laut MEDLINE: Urinary Catheters, Catheters, Indwelling, Urinary Catheterization, Catheter-Related Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Katheterassoziierte Infektionen
Abstract (Originalsprache)
Objective
Catheter-associated urinary tract infections (CAUTIs) are prevalent healthcare-associated infections, arising from biofilm-forming bacteria. This may be prevented by coating the catheter with an antifouling substance. The novel LubriShield™ Foley catheter is coated with a superhydrophilic surface and a covalently bonded antifouling ligand. Preclinical studies revealed that the coating established a persistent local antifouling environment, inhibiting uropathogenic bacteria from forming biofilms. No substance release has been detected from the coating. The coating achieved a 28-fold reduction in surface friction compared to an uncoated catheter. The aim of this study is to assess the clinical safety of the catheter in patients. Materials & methods: In a prospective single-centre randomised study, 30 patients undergoing transurethral resection of bladder tumour were enrolled and randomly assigned to receive either a standard control catheter or the novel LubriShield™ catheter. Urinary cultures were obtained twice. The duration of catheterisation for the patients ranged from 3 to 24 h. The primary outcome was the assessment of device-specific adverse events (AEs). Secondary outcomes included evaluations of pain, irritation and discomfort, measured using the Numeric Rating Scale (NRS) (0–10) via a patient questionnaire.
Results
There were no serious adverse events (SAEs) or AEs reported for the coated catheters. Urinary cultures showed no significant differences between the coated and uncoated catheters. Both patients and healthcare professionals rated the NRS equally for the two types of catheters.
Conclusions
The novel-coated LubriShield™ catheter was found to be safe for short-term clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Swede…
- Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Urology, Capio Gastro Center, Gothenburg, Sweden.
ORCID-Profile: Anders Andreasson, Teresa Ekerhult, Johan Stranne
Zitieren
APA
Andreasson, A., Andersson, J., Larsson, H., Ekerhult, T., & Stranne, J. (2025). A prospective randomised pilot study evaluating the safety of the novel LubriShield™ Foley catheter: a permanently coated indwelling urinary catheter. Scandinavian Journal of Urology. https://doi.org/10.2340/sju.v60.43994
Vancouver
Andreasson A, Andersson J, Larsson H, Ekerhult T, Stranne J. A prospective randomised pilot study evaluating the safety of the novel LubriShield™ Foley catheter: a permanently coated indwelling urinary catheter. Scandinavian Journal of Urology. 2025. doi:10.2340/sju.v60.43994
BibTeX
@article{Andreasson2025,
author = {Andreasson, Anders and Andersson, Jan and Larsson, Henrik and Ekerhult, Teresa and Stranne, Johan},
title = {A prospective randomised pilot study evaluating the safety of the novel LubriShield™ Foley catheter: a permanently coated indwelling urinary catheter},
journal = {Scandinavian Journal of Urology},
year = {2025},
doi = {10.2340/sju.v60.43994}
}
EUVIMED